Colorectal cancer mouse models: Integrating inflammation and the stroma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 39-50

  Ernst, Matthias ^a,c   Ramsay, Robert G ^b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

Author keywords

Cancer; Colon; Lgr5; Mouse models; Myb; NF B; Small intestine; Stat3; Wnt

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN B1; CYCLIN D1; CYTOCHROME P450 1A1; GLUCOSE REGULATED PROTEIN 78; GLYCOPROTEIN GP 130; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 20; JANUS KINASE 2; MUCIN 2; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 2; PROTEIN MYB; PROTEIN P52; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; VILLIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL NUCLEUS; COLON ADENOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA DAMAGE; ENZYME PHOSPHORYLATION; EXON; GENE DELETION; GENE INDUCTION; HAPLOINSUFFICIENCY; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTESTINE CRYPT; INTESTINE EPITHELIUM; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEM CELL NICHE; STROMA; TRANSCRIPTION INITIATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; UPREGULATION;

EID: 84155192662     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06883.x     Document Type: Article

References (126)

1. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol. 2008; 14: 3937-47.
2. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011; 117: 1163-71.
3. Risques RA, Lai LA, Himmetoglu C etal. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 2011; 71: 1669-79.
4. Din FV, Theodoratou E, Farrington SM etal. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-9.
5. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
6. Cooper K, Squires H, Carroll C etal. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 2010; 14: 1-206.
7. Chulada PC, Thompson MB, Mahler JF etal. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000; 60: 4705-8.
8. Takeda H, Sonoshita M, Oshima H etal. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003; 63: 4872-7.
9. Galon J, Costes A, Sanchez-Cabo F etal. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY.) 2006; 313: 1960-4.
10. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine V. Unitarian theory of the origin of the four epithelial cell types. Am. J. Anat. 1974; 141: 537-61.
11. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine I. Columnar cell. Am. J. Anat. 1974; 141: 461-79.
12. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine III. Entero-endocrine cells. Am. J. Anat. 1974; 141: 503-19.
13. Nichols DB, Cheng H, Leblond CP. Variability of the shape and argentaffinity of the granules in the enteroendocrine cells of the mouse duodenum. J. Histochem. Cytochem. 1974; 22: 929-44.
14. Cheng H, Merzel J, Leblond CP. Renewal of Paneth cells in the small intestine of the mouse. Am. J. Anat. 1969; 126: 507-25.
15. Bach SP, Renehan AG, Potten CS. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 2000; 21: 469-76.
16. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-20.
17. Whitehead RH, Jones JK, Gabriel A, Lukies RE. A new colon carcinoma cell line (LIM1863) that grows as organoids with spontaneous differentiation into crypt-like structures in vitro. Cancer Res. 1987; 47: 2683-9.
18. Barker N, van Es JH, Kuipers J etal. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-7.
19. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 2008; 40: 915-20.
20. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
21. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
22. Berg DJ, Davidson N, Kuhn R etal. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 1996; 98: 1010-20.
23. Sohn KJ, Shah SA, Reid S etal. Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2- and beta(2)-microglobulin-deficient mouse. Cancer Res. 2001; 61: 6912-17.
24. Cammarota R, Bertolini V, Pennesi G etal. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J. Transl. Med. 2010; 8: 112.
25. Hartman ZC, Osada T, Glass O etal. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res. 2010; 70: 7209-20.
26. Salcedo R, Worschech A, Cardone M etal. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 2010; 207: 1625-36.
27. Xiao H, Yin W, Khan MA etal. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 2010; 139: 574-85.
28. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-4.
29. Su LK, Kinzler KW, Vogelstein B etal. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256: 668-70.
30. Shoemaker AR, Luongo C, Moser AR, Marton LJ, Dove WF. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice. Cancer Res. 1997; 57: 1999-2006.
31. Silverman KA, Koratkar R, Siracusa LD, Buchberg AM. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Res. 2002; 12: 88-97.
32. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 2008; 204: 479-90.
33. Gaspar C, Franken P, Molenaar L etal. A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet. 2009; 5: e1000547.
34. Buchert M, Athineos D, Abud HE etal. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet. 2010; 6: e1000816.
35. Fijneman RJ, Cormier RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front. Biosci. 2008; 13: 4144-74.
36. Seno H, Oshima M, Ishikawa TO etal. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002; 62: 506-11.
37. Oshima M, Dinchuk JE, Kargman SL etal. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
38. Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA. Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS ONE 2010; 5: e9070.
39. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 5540-4.
40. Lane SW, Sykes SM, Al-Shahrour F etal. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 2010; 115: 3489-97.
41. You S, Ohmori M, Pena MM etal. Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. Int. J. Exp. Pathol. 2006; 87: 227-36.
42. Coletta PL, Muller AM, Jones EA etal. Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood 2004; 103: 1050-8.
43. Ireland H, Kemp R, Houghton C etal. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 2004; 126: 1236-46.
44. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 2002; 277: 33275-83.
45. el Marjou F, Janssen KP, Chang BH etal. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004; 39: 186-93.
46. Hinoi T, Akyol A, Theisen BK etal. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 2007; 67: 9721-30.
47. Malaterre J, Carpinelli M, Ernst M etal. c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 3829-34.
48. Snippert HJ, van der Flier LG, Sato T etal. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 2010; 143: 134-44.
49. Ireland H, Houghton C, Howard L, Winton DJ. Cellular inheritance of a Cre-activated reporter gene to determine Paneth cell longevity in the murine small intestine. Dev. Dyn. 2005; 233: 1332-6.
50. Barker N, Ridgway RA, van Es JH etal. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608-11.
51. Harada N, Tamai Y, Ishikawa T etal. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999; 18: 5931-42.
52. Fiala ES. Investigations into the metabolism and mode of action of the colon carcinogens 1, 2-dimethylhydrazine and azoxymethane. Cancer 1977; 40: 2436-45.
53. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
54. Lerner I, Hermano E, Zcharia E etal. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 2011; 121: 1709-21.
55. Saleh M, Elson CO. Experimental inflammatory bowel disease: insights into the host-microbiota dialog. Immunity 2011; 34: 293-302.
56. Waldner MJ, Wirtz S, Becker C etal. Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer. Inflamm. Bowel Dis. 2010; 16: 559-67.
57. Schiechl G, Bauer B, Fuss I etal. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. J. Clin. Invest. 2011; 121: 1692-708.
58. Osawa E, Nakajima A, Fujisawa T etal. Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int. J. Cancer 2006; 118: 2232-6.
59. Cooper HS, Everley L, Chang WC etal. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 2001; 121: 1407-16.
60. Ju J, Nolan B, Cheh M etal. Voluntary exercise inhibits intestinal tumorigenesis in Apc(Min/+) mice and azoxymethane/dextran sulfate sodium-treated mice. BMC Cancer 2008; 8: 316.
61. Tanaka T, Kohno H, Suzuki R etal. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006; 118: 25-34.
62. Maltzman T, Whittington J, Driggers L, Stephens J, Ao AD. M-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997; 18: 2435-9.
63. Sheng H, Shao J, Williams CS etal. Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis 1998; 19: 543-9.
64. Suzui M, Okuno M, Tanaka T, Nakagama H, Moriwaki H. Enhanced colon carcinogenesis induced by azoxymethane in min mice occurs via a mechanism independent of beta-catenin mutation. Cancer Lett. 2002; 183: 31-41.
65. Albuquerque C, Breukel C, van der Luijt R etal. The "just-right" signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum. Mol. Genet. 2002; 11: 1549-60.
66. Janssen KP, Alberici P, Fsihi H etal. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131: 1096-109.
67. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Kirkpatrick CJ. Loss of E-cadherin in the vicinity of necrosis in colorectal carcinomas: association with NFkappaB expression. Int. J. Oncol. 2007; 31: 269-75.
68. Kojima M, Morisaki T, Sasaki N etal. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004; 24: 675-81.
69. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998; 95: 729-31.
70. Lin R, Gewert D, Hiscott J. Differential transcriptional activation in vitro by NF-kappa B/Rel proteins. J. Biol. Chem. 1995; 270: 3123-31.
71. Egan LJ, Eckmann L, Greten FR etal. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 2452-7.
72. Greten FR, Eckmann L, Greten TF etal. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
73. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14 e5.
74. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect Biol. 2009; 1: a000141.
75. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. 2009; 9: 798-809.
76. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004; 20: 23-32.
77. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002; 109: 1139-42.
78. Morikawa T, Baba Y, Yamauchi M etal. STAT3 expression, molecular features, inflammation patterns and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 2011; 17: 1452-62.
79. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med. 2008; 59: 213-22.
80. Rebouissou S, Amessou M, Couchy G etal. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Nature 2009; 457: 200-4.
81. He B, You L, Uematsu K etal. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 14133-8.
82. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 1397-402.
83. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div. 2010; 5: 14.
84. Bollrath J, Phesse TJ, von Burstin VA etal. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
85. Grivennikov S, Karin E, Terzic J etal. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
86. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
87. Ernst M, Najdovska M, Grail D etal. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 2008; 118: 1727-38.
88. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat. Rev. Cancer 2008; 8: 523-34.
89. Ramsay RG, Malaterre J. Insights into c-Myb functions through investigating colonic crypts. Blood Cells Mol. Dis. 2007; 39: 287-91.
90. Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992; 3: 723-30.
91. Thompson MA, Rosenthal MA, Ellis SL etal. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res. 1998; 58: 5168-75.
92. Biroccio A, Benassi B, D'Agnano I etal. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am. J. Pathol. 2001; 158: 1289-99.
93. Ciznadija D, Tothill R, Waterman ML etal. Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. Cell Death Differ. 2009; 16: 1530-38.
94. Zorbas M, Sicurella C, Bertoncello I etal. c-Myb is critical for murine colon development. Oncogene 1999; 18: 5821-30.
95. Ramsay RG, Friend A, Vizantios Y etal. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000; 60: 1805-9.
96. Ramsay RG, Ciznadija D, Mantamadiotis T, Anderson R, Pearson R. Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. Int. J. Biochem. Cell Biol. 2005; 37: 1254-68.
97. Takahashi H, Wang JP, Zheng HC, Masuda S, Takano Y. Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis. Histol. Histopathol. 2011; 26: 663-71.
98. Winder T, Bohanes P, Zhang W etal. GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Ann. Oncol. 2011.
99. Xing X, Li Y, Liu H, Wang L, Sun L. Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis. Acta Histochem. 2010.
100. Bertolotti A, Wang X, Novoa I etal. Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. J. Clin. Invest. 2001; 107: 585-93.
101. Gao Q, Esworthy RS, Kim BW, Synold TW, Smith DD, Chu FF. Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase. Inflamm. Bowel Dis. 2010; 16: 2043-54.
102. Shkoda A, Ruiz PA, Daniel H etal. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 2007; 132: 190-207.
103. Hugo H, Cures A, Suraweera N etal. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-54.
104. Sicurella C, Freeman R, Micallef S, Mucenski ML, Bertoncello I, Ramsay RG. Defective stem cell factor expression in c-myb null fetal liver stroma. Blood Cells Mol. Dis. 2001; 27: 470-8.
105. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009; 15: 416-28.
106. Lee H, Herrmann A, Deng JH etal. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283-93.
107. Liao J, Humphrey SE, Poston S, Taparowsky EJ. Batf promotes growth arrest and terminal differentiation of mouse myeloid leukemia cells. Mol. Cancer Res. 2011; 9: 350-63.
108. Toth CR, Hostutler RF, Baldwin AS Jr, Bender TP. Members of the nuclear factor kappa B family transactivate the murine c-myb gene. J. Biol. Chem. 1995; 270: 7661-71.
109. Suhasini M, Reddy CD, Reddy EP, DiDonato JA, Pilz RB. cAMP-induced NF-kappaB (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation. Oncogene 1997; 15: 1859-70.
110. Kataoka Y, Murley JS, Khodarev NN, Weichselbaum RR, Grdina DJ. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53: 180-9.
111. Ishikawa TO, Oshima M, Herschman HR. Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis 2011; 32: 417-26.
112. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000; 118: 337-45.
113. Ramsay RG, Ciznadija D, Vanevski M, Mantamadiotis T. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int. J. Immunopathol. Pharmacol. 2003; 16: 59-67.
114. Araki Y, Okamura S, Hussain SP etal. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 2003; 63: 728-34.
115. Plummer SM, Holloway KA, Manson MM etal. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999; 18: 6013-20.
116. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell. Mol. Immunol. 2009; 6: 327-34.
117. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 2004; 172: 567-76.
118. van der Flier LG, van Gijn ME, Hatzis P etal. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009; 136: 903-12.
119. Sato T, Vries RG, Snippert HJ etal. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-5.
120. Sato T, van Es JH, Snippert HJ etal. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 469: 415-8.
121. Huynh D, Dai XM, Nandi S etal. Colony stimulating factor-1 dependence of paneth cell development in the mouse small intestine. Gastroenterology 2009; 137: 136-44.
122. Xu H, Balakrishnan K, Malaterre J etal. Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice. PLoS ONE 2010; 5: e12112.
123. Sikandar SS, Pate KT, Anderson S etal. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010; 70: 1469-78.
124. Merlos-Suarez A, Barriga FM, Jung P etal. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-24.
125. Cheasley D, Pereira L, Lightowler S etal. Myb controls intestinal stem cell genes and self-renewal. Stem Cells 2011 (in press).
126. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-10.